Connection between circadian rhythms and neurodegenerative diseases

Yue Leng, PhD1,2*, Erik S. Musiek, MD, PhD3, Kun Hu, PhD4,5, Francesco P. Cappuccio, MD, FRCP6
Kristine Yaffe, MD7

1. Department of Psychiatry, University of California, San Francisco, 4150 Clement Street, San Francisco VA Medical Center, CA 94121, USA
2. Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, China
3. Department of Neurology, Hope Center for Neurological Disorders, and Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA
4. Medical Biodynamics Program, Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women’s Hospital, Boston, MA 02115, USA
5. Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
6. Division of Health Sciences (Mental Health and Wellbeing), Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
7. Departments of Psychiatry, Neurology, and Epidemiology, University of California, San Francisco, San Francisco VA Medical Center, San Francisco, CA 94121, USA.

* Corresponding author: 4150 Clement Street, San Francisco VA Medical Center, San Francisco, CA. Email: yue.leng@ucsf.edu. Tel: 415-221-4810
I. Abstract

Increasingly circadian rhythms have been linked to age-related diseases. We provide an up-to-date review (2013-2018) of the association between circadian rhythm disruptions (CRD) and the most common types of neurodegenerative diseases, including Alzheimer’s disease and related dementias (ADRD) and Parkinson’s disease (PD). CRD differ according to type and severity of neurodegenerative diseases, and importantly, could occur early during the course of neurodegeneration as a prodrome. Evolving evidence also supports CRD as a potential risk factor for developing ADRD and PD, although confirmatory studies are needed. Proposed mechanistic pathways underlying this association include alterations in sleep, protein homeostasis, and immune and inflammatory function. While promising, more studies of CRD and treatment trials are needed to determine whether circadian interventions may prevent or delay the onset of neurodegenerative diseases. The study of circadian rhythms holds great promise for a role in the prevention and management of neurodegenerative diseases.
Glossary Panel

**Amplitude:** Magnitude of a cycle, or the difference between peak and trough values. In relation to a hormonal cycle, for example, it would be the difference in the levels of the hormone from the trough to the peak within a time period (i.e. 24 hours).

**Circadian rhythm:** An approximately 24-hour cycle in the physiological processes of most organisms, endogenously generated, and modulated by external cues.

**Circadian rhythm sleep-wake disorders:** Disorders related to the timing of sleep and wakefulness that are characterized by the inability to fall asleep, remain asleep, and/or wake at the desired time.

**Circadian misalignment:** A loss of synchrony between internal circadian rhythms, behaviors and the external environment, as a result of a variety of circumstances (e.g. jet lag, shift work).

**Entrainment:** The resetting of circadian cycle to maintain synchrony with daily environmental and behavioral cycle.

**Irregular sleep-wake rhythm disorder:** A lack of clear 24-hour sleep-wake pattern, usually with long periods of wakefulness during the night and irregular bouts of sleep throughout the day; most common in patients with neurodegenerative diseases.

**Mesor:** The mean value around which the rhythm oscillates.

**Period:** Time interval between two reference points within a rhythm or recurring wave.

**Phase:** Timing of a reference point in the cycle relative to a fixed event. In relation to a sleep-wake cycle, for example, a phase advance (delay) would mean that sleep timing moves earlier (later).

**Sundowning:** Increasing behavioral and neuropsychiatric symptoms around the time of sunset, commonly seen in dementia patients.

**Zeitgeber:** an external or environmental cue (e.g. light, temperature) that synchronizes an organism’s internal biological rhythms to the external 24-hour light-dark cycle.

Panel 1.
II. Introduction

The award of the 2017 Nobel Prize in Physiology or Medicine to Hall, Rosbash, and Young for their work on the molecular mechanisms of the circadian clock highlights the importance of circadian rhythms and their relation to health and wellbeing (1). In humans, circadian rhythm activities change markedly as people age, and these changes might further accelerate the aging process (2). While it is recognized that circadian dysfunction in older adults can be partly attributed to the degeneration of the suprachiasmatic nucleus (SCN), known as the “master circadian clock” in mammals, the link between circadian rhythms and neurodegeneration is not fully understood. Patients with neurodegenerative diseases frequently experience circadian rhythm disruptions (CRD) (3-5). For example, they become more active during the night, less active during the day, and sometimes have complete reversal or loss of the 24-h rest-activity pattern (6, 7). Importantly, growing evidence suggests that disruptions of circadian functions could be early manifestations of neurodegeneration, and might even be a risk factor to the development of neurodegenerative diseases in healthy older adults (8-10). Greater understanding of the relationship between circadian rhythms and neurodegeneration could be key to the early identification and management of neurodegenerative diseases.

This review discusses the association between circadian rhythms and neurodegenerative diseases by summarizing evidence from both human and animal studies. In order to provide a most up-to-date review of the evidence, we mainly discuss the empirical findings published within the past 5 years, except for certain landmark studies. We referred to a few previous reviews (11-13) for detailed discussion of earlier studies. This review focuses on Alzheimer’s disease and related dementias (ADRD) and Parkinson’s disease (PD), as these are the most common neurodegenerative diseases and have been studied most in relation to circadian rhythms. We
introduce key concepts related to circadian rhythms (See Glossary Panel), present both behavioral and biological circadian features in patients with ADRD and PD, summarize findings from clinical and longitudinal epidemiologic studies regarding the effects of CRD on the development of ADRD and PD, and discuss underlying mechanisms. Finally, we describe the results of different circadian interventions, especially in those with ADRD and PD, and discuss future directions.

III. Circadian rhythms

A circadian rhythm (from the Latin ‘circa’ = about and ‘diem’ = a day) is an approximately 24-hour cycle in the physiological processes of most organisms that is endogenously generated and can be modulated by external cues (14). A circadian cycle is characterized by several features. It is self-sustained, as the rhythm persists in the absence of any exogenous time signals (Zeitgebers), including dark-light cycles. This characteristic indicates the presence of an intrinsic time-keeping mechanism (i.e. biological clock). It shows rhythmicity, as they persist with a cycle of approximately 24 hours. It also shows the ability to be synchronized by external cues, such as the dark-light cycle or other social and environmental modulators, like activity and temperature. The circadian rhythmicity is typically measured by three parameters: amplitude, phase and period. Amplitude is defined as the magnitude of a cycle, or the difference between crest and trough values. In relation to a hormonal cycle, for example, it would be the difference in the levels of the hormone from the trough to the peak within a time period (i.e. 24 hours). Phase (advanced or delayed) is defined as the timing of a reference point in the cycle relative to a fixed event. In relation to a sleep-wake cycle, for example, a phase advance (delay) would mean that sleep timing moves earlier (later). Period is the time interval between two reference points within a rhythm or recurring wave (for example between two hormonal peaks).
Circadian rhythms are generated in highly specialized cells of specific structures of the brain that control a complex network of coupled self-sustained clocks in the brain and in the peripheral organs. In mammals, the central or master clock of the circadian network is located in two groups of neurons called the SCN, in the anterior hypothalamus. The SCN consists of approximately 20,000 specialized neurons, which receive direct synaptic input from the retina, synchronizing activity to the external light-dark cycle (15). Light input serves to synchronize the core cellular clock machinery in SCN neurons, which keeps 24-hour time and in turn synchronize cellular clocks throughout the body via neurohormonal modulation. At the molecular level, the properties of circadian clocks are based on changes in the expression of certain genes and consist of proteins which form a transcriptional-translation feedback loop that is tuned to a 24-hour period (16). The clock proteins BMAL1 and Clock interact to drive transcription of clock-controlled genes, including their own negative feedback repressors, which include PERIOD, CRYPTOCHROME, and REV-ERB proteins (17). This transcriptional feedback loop maintains 24-hour rhythms in gene expression which are required for behavioral and physiologic rhythmicity at the organismal level. While light is the primary circadian cue, resetting the circadian cycle in synchrony with the daily environmental and behavioral cycle (entrainment) is achieved through the 24-h cycle of light input (photic synchronizer) to the SCN and neurohormonal modulations (non-photic synchronizers) (e.g. temperature, food availability, social interactions) for the peripheral ones. Importantly, in the absence of external cues, such as in constant darkness, the circadian system retains a near 24-hour rhythm, while light cues that are out of phase with the SCN cause a gradual resetting of the clock to entrain to the new rhythm.
The pattern of one’s circadian rhythm can be measured with both biological and behavioral markers. Landmark experiments by Czeisler et al. (18) identified core body temperature (CBT), as well as melatonin and cortisol secretions, as ‘circadian’ biomarkers, oscillations of which are controlled by the SCN. In normally entrained individuals, CBT has a rhythm that falls during the night and rises in the early hours of the morning; cortisol peaks in blood and saliva early in the morning, then regularly decreases throughout late morning and afternoon, to reach low values during evening and night, thereby availing sleep; melatonin is generated by the pineal gland, with its onset near sunset, peak during the nighttime hours and offset after sun rise, thereby stimulating wakefulness. The circadian rhythm of melatonin in saliva or plasma is one of the most commonly used circadian phase biomarkers in human beings (19). The onset time of melatonin secretion under dim light conditions, known as the dim light melatonin onset (DLMO), has been suggested as the single most accurate circadian phase marker in humans (20).

Behavioral markers of circadian rhythm mainly include sleep-wake cycles and rest-activity rhythms. The circadian system has powerful influence over the sleep-wake cycle, such that it is often difficult to distinguish the relative contributions of the two sleep regulatory systems (the sleep-wake homeostasis and the circadian timing system) to behavior. The circadian clock regulates the timing of sleep, as mutations in core circadian clock genes in mice and humans manifest as sleep phenotypes, including short sleep time, early or late sleep phase, or fragmented sleep-wake rhythms (21, 22). Moreover, clock gene expression can be influenced by sleep deprivation, emphasizing that these systems are interrelated. While specific circadian analyses can be used to parse out aspects of CRD from behavioral data, activity must be monitored around the clock for several days. Some circadian biomarkers, such as the timing of melatonin secretion or oscillation of selected clock genes in blood, maintain their 24-hour oscillations even in the
face of sleep deprivation (23, 24). Therefore, it is important for studies to include both behavioral and biological markers of circadian rhythms to more robustly identify CRD. Given the scope of this review, we include studies if they present information on biological markers or behavioral markers related to sleep timing, daytime sleep/sleepiness and rest-activity rhythm; studies that only present nocturnal sleep disruptions are excluded.

Age-related changes in any of the structures or processes involved in generating or entraining circadian rhythms may modify circadian rhythmicity with advancing age. In particular, circadian phase has been shown to move earlier, or advance, with age (25), while the amplitude of the rhythms tend to decrease (26). For example, older adults have decreased peak melatonin, elevated nadir level of CBT, and a phase advance (earlier onset) in the peak of these rhythms (27). Age-related changes in sleep-wake cycles may be related to circadian dysfunction and include earlier bedtimes and rise times, increased sleep fragmentation, and increased daytime sleepiness that has been frequently suggested as an early indicator of declining health in the elderly (29, 30). Duffy et al. reported that older adults are more prone to several circadian rhythm sleep-wake disorders (CRSWDs), including advanced sleep wake phase disorders (ASWPD), jet lag disorder and shift-work disorder, due to an inability to fall asleep or remain asleep, conflicting with desired sleep timing (31, 32). The circadian system is paramount for optimal biological functioning, maintaining synchrony between internal physiology, behavior, and the cues deriving from the external environment. When this synchrony is lost, e.g. due to jet lag, shift work, or chronic sleep deprivation, a “circadian misalignment” occurs, leading to significant health consequences affecting cardiovascular, metabolic, cognitive, immunological and oncogenic processes, with impact also on safety, performance and productivity (33-35).
IV. Disruption in neurodegeneration

a. Alzheimer disease and related dementias

The prevalence of circadian disruption in patients with moderate-to-severe AD has been recognized for more than two decades (6). AD patients were often considered to have much more severe circadian disruptions compared to healthy older adults, including higher fragmentations, dampened amplitude and phase delay, as opposed to more typical advanced circadian phase associated with normal aging (6). It was suggested that “sundowning”, known as the increasing behavioral and neuropsychiatric symptoms in AD patients around the time of sunset, could also partly be attributed to the phase delay of temperature and hormone rhythms in AD (36)(37). The most common CRSWD seen in AD patients is irregular sleep-wake rhythm disorder (ISWRD), as opposed to ASWRD in healthy older adults. ISWRD is defined as a lack of clear 24-hour sleep-wake pattern, usually with long periods of wakefulness during the night and irregular bouts of sleep throughout the day which might get worse in severe AD (38, 39).

Over the past five years, a growing number of studies focused on patients of various levels of cognitive impairment and found their circadian patterns differed from those reported in previous studies (6). These studies (Table 1) included patients with pre-clinical AD (8), mild cognitive impairment (MCI) (40) (41), mild AD (3) (42) (43), moderate to severe AD (43), global AD(44), as well as early onset dementia (EOD) (4). All of these studies have reported on behavioral markers of CRD, including disruptions of rest-activity rhythms and sleep timing. Two studies (3, 40) examined melatonin rhythms using saliva melatonin assay, one study (41) assessed temperature rhythms using a wrist temperature sensor, and one study (3) also examined peripheral clock gene expression. Overall, studies have found high rest-activity rhythm fragmentation(4) (8) but only a slight reduction or no change in the amplitude of rest-activity or
melatonin rhythms (3, 4, 8, 42, 44). One recent US study in 189 cognitive normal older adults (50 with preclinical AD pathology) showed decreased rhythm amplitude associated with aging, but not with AD pathology (8). Another study in 16 mild-moderate AD patients from Italy found large variability among individual actigraphic profiles, which could have also contributed to the overall minor changes in the amplitude of rhythms in these patients (42). There are mixed findings with regard to changes in circadian phases. The Rush Memory and Aging Project suggested a significant phase delay in rest-activity rhythm among 7 AD patients compared to 10 controls (44), whereas a study of 48 AD patients from Italy showed an advanced bedtime in AD, especially for moderate to severe cases of AD (43). Meanwhile, two recent studies of MCI patients both found a phase advance, one in melatonin and sleep onset (40), and another in CBT and activity rhythm (41).

In general, studies that focused on more severe AD found more circadian disruptions, while studies in MCI, preclinical AD and mild AD suggested moderate circadian changes (3) (8) (40). Weissova et al. found no correlation between circadian features and severity measures of AD in 16 mild to moderate AD patients (42). No study to date has examined change in circadian rhythms with the progression of AD symptoms. Few studies have examined molecular perturbations in circadian clock oscillations in ADRD, though alteration in clock gene methylation and expression have been described in patient fibroblasts (45), and altered clock gene expression noted in post-mortem tissue (46). Further, evidence specifically pertaining to circadian disruptions among patients with non-AD dementia is sparse. Larger and longitudinal studies are needed to determine the correlation between both behavioral and biological markers of CRD and severity or progression of AD. Additional studies designed to establish circadian
markers and features specific to each type of dementia might help with the differential diagnosis of the disease.

b. Parkinson’s disease

Both motor and non-motor manifestations of PD show disruptions in their typical 24-h oscillations. Unlike patients with ADRD, CRD among PD patients is featured by a reduction in the amplitude of the circadian rhythm but no significant shift in circadian phases (5) (47) (48) (49) (50) (51). Sleep-wake disturbances as a whole are the most common non-motor symptom of PD patients, affecting up to 80% of PD patients (52). Indeed, five of the six studies (Table 2) that examined circadian features in PD patients reported on either excessive daytime sleepiness (EDS) (5) (47) (48) or sleep timing (48) (51) (49). It was reported that PD patients were at least twice as likely to experience EDS compared to healthy older adults (5, 47). Only one study reported slightly later sleep onset time in 30 PD patients compared to 15 healthy controls from England (53), while the others did not find significant differences in sleep timing (49, 51). One Australian study found among 12 PD patients a significant reduction in the mesor (mean value around which the rhythm oscillates) and amplitude of their CBT rhythm, compared to 11 healthy controls(49). Three studies examined rhythms of melatonin secretion, using plasma (5), serum (48) and saliva melatonin (51), respectively. While none of these studies found a difference in the timing of melatonin onset, most found significantly reduced circulating melatonin levels among PD patients (5) (48). Importantly, the usual circadian dip in blood pressure during the night may be lost in PD, putting patients at significantly higher risk for cardiovascular complications including nocturnal hypertension (50). For example, a study of 111 PD patients from Spain reported that 71.1% of patients did not have the usual dip in blood pressure as measured by 24-h ambulatory blood pressure monitoring (50).
Despite the consistently reported CRD among PD patients, it remains unclear whether these circadian changes result from dopaminergic treatment or PD disease progression itself. Earlier studies reported that the dopaminergic treatment might lead to phase advance of the melatonin rhythm\(54, 55\), while a more recent study among 29 PD patients (16 medicated and 13 non-medicated) and 28 healthy controls from Australia found more than double the melatonin secretion and uncoupling of circadian and sleep-wake regulations in the treatment group \(51\). EDS is another potential consequence of dopaminergic treatment \(47\). One study in Norway suggested a doubled frequency of EDS among 153 drug-naive patients with early PD, compared to 169 age- and sex-matched controls at baseline, and a tripled frequency of EDS among these patients after 5 years of dopaminergic treatment compared to the controls \(47\). Larger studies with other circadian markers are needed to help clarify the effects of dopaminergic treatment on circadian rhythms, relative to neurodegeneration per se.

V. Disruption and risk of neurodegeneration

A critical question is whether CRD is a cause or consequence of neurodegeneration, or both. If CRD were contributing to neurodegeneration, it would be expected to occur early in disease course (or precede disease), and would increase disease risk or rate of progression. While this question is still unanswered, growing evidence suggests that CRD might precede the development of clinical symptoms of neurodegenerative diseases. One recent study of 189 cognitively normal older adults (50 with preclinical AD) reported that circadian rest-activity rhythm fragmentation appeared very early on in the preclinical phase of AD and correlated with AD-related pathology as assessed with PET imaging and cerebrospinal fluid (CSF) phosphorylated tau to amyloid β (Aβ)42 ratio \(8\). Several studies found a correlation between sleep-wake disturbances and increased levels of AD-related biomarkers or brain structural
change in cognitively normal older adults, though other biological markers of CRD were not specifically examined (10, 56, 57). Alterations in circadian melatonin rhythm were also found in healthy middle-aged men with worse cognitive trajectories in midlife (58). These cross-sectional findings suggested that CRD could be a result of preclinical AD pathology and may be a prodromal symptom or sign.

Several longitudinal studies with long follow-up periods also reported greater cognitive decline, increased risk of all-cause dementia and increased risk of PD among those with circadian disturbances, including shift work (59-63). Table 3 shows longitudinal studies on CRD and risk of developing ADRD or PD published over the past five years. These studies all examined behavioral indicators of CRD, including actigraphy-measured rest-activity rhythm and daytime napping (9, 61, 64) and self-reported sleep timing(65). Two studies both found an association between lower circadian amplitude and greater cognitive decline over the next 3-5 years, in cognitively normal older men (64) and women (61) from the US. Bokenberger et al. reported in 11,247 individuals from the Swedish Twin Registry that delayed rising time predicted dementia incidence over 17 years (65). Another recent study of 2920 older men from the US suggested that those who napped for at least 1h per day were twice as likely to develop PD in 11 years (9). While all together these studies suggest that reduced circadian amplitude and circadian phase shifts precede the risk of ADRD, and that daytime inactivity precedes the risk of PD in healthy older adults, the number of published studies is small especially for PD. Additional confirmatory studies with long follow-up period are needed to determine whether CRD is a risk factor for ADRD and PD. Comprehensive and repeated measures of CRD with simultaneous assessment of preclinical disease biomarkers (such as amyloid and tau pathology) will also help understand the nature of this association.
VI. Underlying mechanisms

a. Effects of neurodegenerative disease pathology on circadian clock function

The mechanisms by which neurodegenerative pathology affects circadian function likely vary by specific disease. In AD, human post-mortem neuropathological studies have demonstrated loss of critical neuronal populations in the SCN, including those expressing arginine vasopressin (AVP) or vasoactive intestinal peptide (VIP) (44, 66). Both age- and AD-associated loss of VIP-expressing neurons in the SCN were correlated with pre-mortem circadian dysfunction (Fig.1). However, the mechanisms driving SCN neuronal loss are unclear, as it is not a major site of amyloid plaque or neurofibrillary pathology. Circadian abnormalities are observed in transgenic mouse models of AD, including those expressing human mutant amyloid precursor protein (APP), tau, or both. However, there is great heterogeneity across mouse models, and little correlation with pathology, obscuring any definitive mechanistic conclusions (67-69). Aβ peptide has been implicated as a mediator of circadian dysfunction, and in cultured cells it can induce degradation of the master clock protein BMAL1 (70, 71). However, this direct interaction between Aβ and the circadian clock has not been demonstrated in vivo in animals, or in humans. Altered methylation of the BMAL1 promoter, leading to altered BMAL1 expression and disrupted circadian rhythms, was described in fibroblasts from AD patients and in post-mortem AD brain samples, suggesting an underlying epigenetic mechanism of circadian disruption in AD (Fig.1) (45).

b. Effects of circadian disruption on neurodegeneration

There are several proposed mechanisms by which the circadian clock influences neurodegenerative disease (Fig. 1). Circadian dysfunction could promote neurodegeneration by altering sleep timing, leading to less consolidated nighttime sleep and increased daytime
napping. Sleep deprivation causes altered Aβ dynamics in humans and increased Aβ and tau pathology in mouse models, and can increase inflammatory and neuronal injury markers in human cerebrospinal fluid (72-75). Sleep deprivation can also impact other aspects of neurodegeneration including protein clearance from the brain, inflammation, and synaptic homeostasis (76, 77). In this case, intervention to promote sleep should overcome any effect of circadian disruption. However, in mouse models, clock gene deletion in the brain can cause neuropathology without altering sleep, suggesting that sleep alone may not explain the brain effects of circadian disruption (78).

Circadian regulation of immune responses may also contribute to the effects of circadian dysfunction on neurodegeneration. The circadian system strongly modulates the peripheral immune response to inflammmogens, as the degree of inflammation is highly dependent on time-of-day of exposure (79, 80). In a mouse experimental autoimmune encephalitis model of neuroinflammation, the time of day of immunization has a striking impact on disease severity weeks later, while deletion of Bmal1 in myeloid cells exacerbates pathology (81, 82). In the brain, microglia and astrocytes represent the primary innate immune cells, and both cell types possess functional circadian clocks which regulate inflammatory activation (83, 84). Deletion of Bmal1 in the brain, which disrupts all circadian clock function, causes widespread astrocyte activation and synaptic degeneration, emphasizing the importance of core clock function in maintaining innate immune homeostasis in the brain (78). In mouse models of Amyotrophic Lateral Sclerosis and PD, circadian disruption using non-24 hour light dark cycles led to increased glial activation and neuroinflammation and exacerbated neuropathology (85, 86). Thus, circadian dysfunction appears to promote aspects of neuroinflammation, which could influence neurodegeneration in many disease states.
The circadian clock could directly regulate protein homeostasis and quality control, thereby influencing protein aggregation in neurodegenerative diseases (87). In AD, levels of interstitial fluid Aβ peptide in the hippocampus show clear diurnal oscillation, which require an intact circadian system (88, 89). Similar diurnal oscillations in Aβ are observed in human cerebrospinal fluid (90). Moreover, disruption of the circadian clock in a mouse β-amyloidosis model of AD leads to accelerated amyloid plaque deposition (89). Circadian regulation in protein quality control systems, such as autophagy, may contribute to the circadian influence on protein aggregation in general (91, 92). Bulk removal of aggregated proteins from the brain by the glymphatic system, a glia-mediated perivascular fluid flow, has been associated with sleep, but its relation to the circadian system and the role of glial clocks in the process are still unclear (76). Recent studies demonstrating circadian clock control of blood-brain barrier permeability may also have implications for protein aggregates clearance from the brain (93, 94). Finally, numerous studies reveal a complex, bidirectional relationship between the circadian clock and oxidative stress, a key pathogenic process in neurodegeneration (78, 95-98). Thus, a number of potential identified mechanisms, as well as those which are not yet known, could link the circadian clock to neurodegenerative diseases.

VII. Circadian Interventions

If circadian dysfunction is a risk factor contributing to the development of neurodegenerative diseases, one of the appealing testable hypotheses is that enhancing circadian rhythms might prevent or halt the progress of these diseases as well as mitigating their related symptoms. Limited earlier studies have tested this hypothesis using timed light and/or melatonin treatments but provided inconsistent results (see Review by Forbes, et al.(99)). For instance, in a double-blind, placebo-controlled, 2x2 factorial randomized trial of 189 residents of group care facilities
in the Netherlands (87% had dementia), Riemersma-van der Lek et al. examined the effects of daily treatment with whole-day bright of 1000 lux (as compared to dim light of 300 lux) and daily evening melatonin treatment (as compared to placebo) and found that the long-term light treatment (up to 3.5 years) attenuated cognitive decline with aging and improved depressive symptoms (100). However, Burn et al. did not find similar cognitive benefit of bright light in their randomized controlled trial of 48 patients in two nursing homes in the UK with diagnosed dementia, sleep disruption, and agitated behavior (101). The discrepancy may be attributed to uncontrolled treatment dose such as exposure duration and intensity of light that are especially important for the elderly with reduced response of the circadian system to light exposure (102); future studies should examine these possibilities.

In the last five years, only two published circadian intervention studies examined patients with ADRD or PD. In a multicenter (one in the UK and four in the USA), double-blinded, parallel-group study (103), sixty patients diagnosed with mild to moderate AD dementia (13 of them had insomnia) were randomized to receiving daily treatment of a prolonged-release melatonin formulation for 24 weeks or placebo. The study showed a positive effect of melatonin treatment on cognitive performance, especially for those with insomnia. The other study was performed in PD centers at Northwestern University and Rush University, where 31 patients with PD and coexistent excessive daytime sleepiness who received stable dopaminergic therapy underwent a 14-day light intervention with twice 1-h exposure to bright or dim light each day (104). The light intervention improved daily activity rhythms and reduced daytime sleepiness, and the effects were stronger with bright light.

The application of circadian interventions in neurodegenerative diseases is a promising but emerging field. Many questions and concerns remain to be addressed. (i) Circadian rhythms can
also be entrained or shifted by many other non-photic time cues or zeitgebers (105), including food (106), caffeine consumption (107) and exercise (108). These zeitgebers affect circadian rhythms likely through direct influences on the peripheral clocks and their feedback to the central circadian clock (109). How to appropriately implement these time cues in circadian interventions requires better understanding of the interactions between the central and peripheral clocks. (ii) The intrinsic properties such as the period of the central circadian clock can be different between individuals, leading to different chronotypes (i.e., evening- and morning-types) and different circadian timings (relative to time of day) of behavior and physiological functions including melatonin secretion. Thus, individuals of different chronotypes have different responses even when light exposure and melatonin are scheduled at the same time of day (110). However, no clinical trials have incorporated chronotype into personalized circadian interventions. (iii) Though circadian control and sleep regulation are tightly coupled, they have different underlying mechanisms. Understanding these specific mechanistic pathways in addition to distinguishing whether the observed beneficial effects of interventions are through the influences on the circadian clocks or directly on the neural circuitry of sleep homeostasis may improve strategies for future drug and therapeutic design. (iv) Despite the association between circadian disturbances and cognitive impairment, more evidence for the impacts of circadian interventions on cognitive decline and the progression of neurodegenerations over a long term (e.g., >5 years), especially after the intervention period, is required. (v) No circadian intervention study has considered neuropathological biomarkers. Using structural MRI or PET scans of the brain and examining longitudinal changes in CSF Aβ and tau levels will help clarify the contributions of circadian disturbances to neuropathological and anatomical changes in the brain, which may provide insights into potential mechanisms. (vi) Previous studies have been exclusively focused
on the stages of neurodegenerative diseases after the clinical onset of the diseases. It will be important to test the benefits of circadian therapies for the prevention of the diseases and related symptoms at preclinical stages.

VIII. Conclusions and future directions

People with ADRD or PD frequently experience disruptions in both behavioral and biological markers of CRD, including disrupted sleep-wake cycles, impaired hormonal and body temperature rhythms, dysregulated autonomic system as well as fluctuated neuropsychiatric symptoms. CRD in neurodegeneration is often presented in a much more severe form than typical age-related CRD and also has distinct features. Unlike healthy older adults who usually have reduced circadian amplitude and advanced circadian phase, patients with ADRD tend to have high fragmentation and slightly reduced amplitude of circadian rhythms. There are mixed findings regarding phase shift among these patients, and they are likely to have irregular sleep-wake patterns. PD patients tend to have reduced circadian amplitude but no change in circadian phases. In general, behavioral CRD markers have been examined more than biological markers. Recent evidence has also suggested that the stage and severity of the disease, as well as the treatment, increase variation in markers of CRD. Larger longitudinal clinical studies are needed to examine the change in circadian rhythms with the progression of neurodegeneration, including non-AD dementias, and to disentangle the effects of PD progression and dopaminergic treatment on circadian rhythms. The integration of non-behavioral circadian biomarkers into these studies would help disentangle CRD from sleep/behavioral confounds (see Directions for future research). This will help identify circadian features that are important for differentiating various types and stages of neurodegenerative diseases, and is important for the management of circadian symptoms in these diseases.
Several epidemiologic studies suggested the presence of circadian disturbances at the preclinical stage of ADRD. CRD might be considered as a useful preclinical marker or prodromal for neurodegenerative diseases and help with the early detection of the disease. Emerging evidence from longitudinal studies also showed that CRD precedes the development of ADRD or PD. Additional confirmatory studies with longer follow-up are needed to examine the relationship between different circadian markers and subsequent risk of developing neurodegenerative diseases, and should consider the use of biomarkers to help understand potential mechanisms. For example, using structural MRI or PET scans of the brain and examining longitudinal changes in CSF Aβ and tau levels will help clarify if circadian disturbances might contribute to AD pathology or structural change in the brain. Studies of biological mechanisms and intervention trials are required to determine if CRD is a cause of neurodegenerative diseases.

Finally, personalized multicomponent circadian intervention should be developed and tested for its benefits on circadian synchronization as well as symptom management of ADRD or PD. In addition, larger longitudinal clinical trials with longer follow-up are also needed to examine the long-term benefits of these interventions, and especially to determine whether these interventions might help prevent or delay the onset of neurodegenerative diseases among healthy older adults, or delay symptoms in those at the preclinical stage. In this way, CRD may be a promising therapeutic target for the prevention and management of neurodegenerative diseases.

**VIII. Search strategy and selection criteria**

We identified references for this Review by searches of PubMed between Jan 2013 and Oct 2018, and by hand searches of reference lists from relevant articles. We used the search terms: “dementia”, “Alzheimer’s disease”, “cognitive function”, “cognitive decline”, “cognition”,

20
“Parkinson disease”, “neurodegeneration” and "circadian rhythm", “circadian clock”, “twenty-four-hour rhythm”, “sleep-wake”, “melatonin” or “chronotherapy”. There were no language restrictions. We included only references published within the past 5 years, except for key or landmark studies in the field. The final reference list was made based on relevance to the theme of this review.
Directions for future research

- Studies of CRD in neurodegeneration should incorporate the assessment of both biological and behavioral markers of CRD.
- Larger, longitudinal studies are needed to determine circadian features for different types and severities of ADRD, and clarify the link between the progression of ADRD and change in circadian rhythm disruptions.
- The interaction between PD disease progression, dopaminergic treatment and circadian changes should be clarified.
- Additional studies with long follow-up period are needed to confirm the effects of CRD on subsequent cognitive decline and risk of developing ADRD or PD.
- Establishment of underlying mechanisms for the bi-directional relationship between circadian rhythms and neurodegeneration are needed to help draw causal inference and inform therapeutic targets.
- The use of circadian interventions in patients with neurodegenerative diseases should be further explored, and personalized circadian treatment should be considered given the large between-individual differences.
- Randomized controlled trials of individuals at preclinical stages are needed to test the benefits of circadian therapies for the prevention of neurodegenerative diseases and related symptoms.

Panel 2.
Declaration of interests

E.S.M receives personal fees from Eisai Pharmaceuticals and GLG Consulting, outside the submitted work.

F.P.C. receives book royalties from Oxford University Press.

K.Y. serves on DSMBs for Takeda, Eli Lilly, and an NIH sponsored study and is a member of the Beeson Scholars in Aging Scientific Advisory Board and a Senate member of the German Center for Neurodegenerative Diseases.

Acknowledgement (Funding Source)

Y.L. is supported by National Institute on Aging (NIA) 1K99AG056598-01. E.S.M is supported by NIA R01AG054517 and the Coins for Alzheimer's Research Trust (CART) Fund. K.H. is supported by NIA R01AG048108 and NIA R01AG059867. K.Y. is supported in part by NIA K24AG031155 and NIA R01AG026720. These organizations had no direct input on any aspect of the paper.

Author contributions

Y.L. and K.Y. conceived the review and developed the outline of this review. All authors contributed to the writing and revision of the manuscript.
<table>
<thead>
<tr>
<th>First author, year</th>
<th>Sample</th>
<th>Type of circadian markers</th>
<th>Measure of circadian markers</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Musiek, 2018(8)</td>
<td>189 cognitively normal older adults (mean age 67y, 50 with preclinical amyloid pathology and 139 amyloid negative)</td>
<td>Rest-activity rhythm</td>
<td>7 to 14-day actigraphy</td>
<td>Those with preclinical AD had increased rest-activity rhythm fragmentation (p=0.008) but no significant difference in the amplitude or phase, after adjusting for age and sex.</td>
</tr>
<tr>
<td>Weissova, 2016(3)</td>
<td>13 mild AD patients and 13 age-matched controls (mean age 78y)</td>
<td>Rest-activity rhythm; melatonin rhythm; peripheral clock gene expression</td>
<td>21-day actigraphy; sleep diary; saliva melatonin assay; realtime polymerase chain reaction</td>
<td>There was a significantly higher number of daytime naps among AD patients (1.76 ± 0.61) than among controls (0.17 ± 0.05); AD patients had dampened melatonin profiles and slightly reduced amplitude of melatonin rhythm; There was no significant difference in PER1 and BMAL1 expression.</td>
</tr>
<tr>
<td>La Morgia, 2016(42)</td>
<td>16 mild-moderate AD patients and 10 age-matched controls (mean age 68y)</td>
<td>Rest-activity rhythm</td>
<td>7-day actigraphy</td>
<td>AD patients had a slightly reduced rhythm amplitude (p=0.04), were less active during the wake period but more active during the night; there were large individual variabilities among AD patients.</td>
</tr>
<tr>
<td>Wang, 2015(44)</td>
<td>7 AD patients and 10 age-matched controls (mean age 90y at death)</td>
<td>Rest-activity rhythm</td>
<td>≥7-day actigraphy within the 18 months prior to death</td>
<td>AD patients had a significant phase delay (activity nadirs and acrophases occurred 2.9 hours later than in controls); there was no significant difference in rhythm amplitude.</td>
</tr>
<tr>
<td>Hooghiemstra, 2015(4)</td>
<td>61 patients with EOD and 67 controls (mean age 62y)</td>
<td>Rest-activity rhythm</td>
<td>7-day actigraphy</td>
<td>Patients with EOD had increased rest-activity rhythm fragmentation (p=0.03) but no significant difference in the amplitude or regularity.</td>
</tr>
<tr>
<td>Liguori, 2014(43)</td>
<td>48 drug-naïve AD patients (21 mild and 27 moderate to severe) and 29 controls (mean age 71y)</td>
<td>Sleep timing</td>
<td>Polysomnography</td>
<td>Those who had AD, especially moderate to severe AD had earlier bedtimes (10:15pm and 9:45pm, respectively), compared to controls (11:30pm) and those with mild AD (10:45); there was no difference in rise times.</td>
</tr>
<tr>
<td>Naismith, 2014(40)</td>
<td>26 MCI patients and 26 age-matched controls (mean age 68y)</td>
<td>Sleep timing; melatonin rhythm</td>
<td>14-day actigraphy; saliva melatonin assay</td>
<td>MCI patients had earlier melatonin and sleep onset compared to controls; there was no significant difference in melatonin levels.</td>
</tr>
<tr>
<td>Ortiz-Tudela, 2014(41)</td>
<td>21 MCI patients and 19 age-matched controls (mean age 73y)</td>
<td>Rest-activity rhythm; temperature rhythm</td>
<td>7-day actimeter; wrist temperature sensor</td>
<td>MCI patients showed a significant phase advance in both temperature and activity rhythm.</td>
</tr>
</tbody>
</table>

AD: Alzheimer’s disease; EOD: Early-onset dementia; MCI: mild cognitive impairment.
Table 2. Case-control studies of circadian rhythm disruptions among patients with Parkinson’s disease (2013-2018)

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Sample</th>
<th>Type of circadian markers</th>
<th>Measure of circadian markers</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tholfsen, 2015 (47)</td>
<td>153 drug-naive PD patients and 169 age- and sex-matched controls (mean age 66y)</td>
<td>EDS</td>
<td>ESS</td>
<td>11.8% PD patients and 4.7% controls had EDS at baseline; after 5 years on PD medication, 23.4% PD patients and 8% controls had EDS. 60% PD patients and 27% controls had EDS (p&lt;0.01); PD patients also had reduced melatonin rhythm amplitude (p&lt;0.001) and 4-fold decrease in 24-h AUC for circulating melatonin levels; there was no significant difference in DLMO.</td>
</tr>
<tr>
<td>Videnovic, 2014 (5)</td>
<td>20 PD patients and 15 age-matched controls (mean age 64y)</td>
<td>Melatonin rhythm; EDS</td>
<td>Plasma melatonin by 24-h repeated blood sampling; ESS</td>
<td>PD patients had more fragmented motor activity during 24-h (p=0.01) and later sleep onset time (p=0.04); they had reduced circulating melatonin levels (p=0.05), increased cortisol levels (p&lt;0.001) and altered Bmal1 expression (p=0.04); there was no difference in the timing of melatonin or cortisol onset or offset. There were no differences in sleep timing or DLMO; dopaminergic treatment more than doubled the melatonin secretion and the phase angle of entrainment.</td>
</tr>
<tr>
<td>Breen, 2014 (48)</td>
<td>30 PD patients and 15 age- and sex-matched controls (mean age at diagnosis 68y)</td>
<td>Sleep timing; EDS; melatonin rhythm; cortisol rhythm; peripheral clock gene expression</td>
<td>14-day actigraphy; ESS; serum melatonin and cortisol by 24-h repeated blood sampling</td>
<td>PD patients had lower temperature mesor (p=0.02) and reduced nocturnal temperature amplitude (p=0.04); there was no significant difference in sleep timing.</td>
</tr>
<tr>
<td>Bolitho, 2014 (51)</td>
<td>29 PD patients (16 medicated and 13 non-medicated) and 28 age-matched controls (mean age 66y)</td>
<td>Sleep timing; melatonin rhythm; phase angle of entrainment</td>
<td>14-day actigraphy and saliva melatonin assay</td>
<td></td>
</tr>
<tr>
<td>Zhong, 2013 (49)</td>
<td>12 PD patients and 11 age-matched controls (mean age 64y)</td>
<td>Sleep timing; core-body temperature profiling</td>
<td>14-day actigraphy; temperature profile recorded by 24-h ingestible capsule sensor</td>
<td></td>
</tr>
<tr>
<td>Berganzo, 2013 (50)</td>
<td>111 PD patients (mean age 68y)</td>
<td>Blood pressure</td>
<td>24-h ambulatory blood pressure monitoring</td>
<td>71.1% of PD patients had no proper physiological circadian rhythm; PD patients had a great burden of nocturnal hypertension.</td>
</tr>
</tbody>
</table>

AUC: Area under the curve; DLMO: Dim light melatonin onset; EDS: Excessive Daytime Sleepiness; ESS: Epworth Sleepiness Scale; PD: Parkinson’s disease.
Table 3. Longitudinal studies on circadian disturbances and subsequent risk of neurodegenerative diseases (2013-2018)

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Sample</th>
<th>Length of follow-up</th>
<th>Type &amp; measure of Circadian measure</th>
<th>Outcome measure</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cognitive impairment including ADRD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rogers-Soeder, 2018 (64)</td>
<td>2754 men (mean age 76y)</td>
<td>3.4y</td>
<td>Actigraphy measured rest-activity rhythm</td>
<td>Cognitive decline by tests of global cognition and executive function</td>
<td>Lower circadian amplitude and phase advance was associated with greater cognitive decline.</td>
</tr>
<tr>
<td>Bokenberger, 2017 (65)</td>
<td>11,247 adults (mean age 73y)</td>
<td>17y</td>
<td>Sleep timing measured by Karolinska Sleep Questionnaire</td>
<td>Incident dementia by ICD-10 codes</td>
<td>Delayed rising time was associated with increased dementia risk.</td>
</tr>
<tr>
<td>Walsh, 2014 (61)</td>
<td>1287 women (mean age 83y)</td>
<td>5y</td>
<td>Actigraphy measured circadian activity rhythm variables</td>
<td>Cognitive decline by tests of global cognition, memory and executive function</td>
<td>Lower circadian amplitude was associated with worse cognitive function, especially executive function.</td>
</tr>
<tr>
<td><strong>Parkinson’s disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leng, 2018 (9)</td>
<td>2920 men (mean age 76y)</td>
<td>11y</td>
<td>Actigraphy measured daytime napping</td>
<td>Incident PD defined by self-report or PD medication use</td>
<td>Long daytime napping was associated with increased risk of PD.</td>
</tr>
</tbody>
</table>

Figure 1. **Hypothesized bi-directional relationship between CRD and neurodegeneration.** The central circadian clock influences sleep timing, which directly controls Aβ dynamics (in humans and mice) and glymphatic clearance of toxic proteins (in animals). Sleep disruption also alters a host of other factors, from synaptic homeostasis to inflammation. Circadian clocks in microglia and astrocytes may regulate the blood/brain barrier (BBB), inflammation, and synaptic function, though this is speculative. Animal studies suggest that circadian clocks in neurons influence brain oxidative stress, and could affect brain metabolic function and synaptic homeostasis. Finally, peripheral clocks in organs such as the gut and liver impact peripheral metabolism, the microbiome, and immune function. In total, this multi-system perturbation could promote toxic protein aggregation and neurodegeneration, which in turn could disrupt circadian clocks in the SCN and periphery. Black arrows=supported by human data, Blue arrows=supported by animal data, Grey arrows=speculative.
References


